Valuation : Glaukos Corporation

Market Cap 10.6B 9.14B 8.57B 7.82B 14.73B 1,014B 14.78B 102B 39.66B 512B 39.81B 38.95B 1,696B P/E 2026 *
-222x
P/E 2027 * 612x
Enterprise Value 10.43B 8.99B 8.43B 7.69B 14.49B 997B 14.54B 99.97B 39.01B 503B 39.16B 38.31B 1,668B EV / Sales 2026 *
15.1x
EV / Sales 2027 * 12.2x
Free-Float
96.35%
Yield 2026 *
-
Yield 2027 * -
1 day-1.12%
1 week-2.72%
Current month+7.89%
1 month+18.86%
3 months+68.86%
6 months+49.39%
Current year+59.30%
1 week 176.82
Extreme 176.82
187.14
1 month 165.37
Extreme 165.37
191.62
Current year 93.96
Extreme 93.96
191.62
1 year 73.16
Extreme 73.16
191.62
3 years 59.22
Extreme 59.22
191.62
5 years 33.33
Extreme 33.33
191.62
10 years 23.08
Extreme 23.075
191.62
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap.
19/08/26 Fiscal year

Director

7,500 0.0131%
11/08/26 Fiscal year

Chairperson

180,000 0.3139%
07/08/26 Fiscal year

Chief Financial Officer

60,000 0.1046%
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%-2.72%+86.28%+143.00% 10.6B
+2.66%+0.38%-15.14%+18.82% 127B
-0.93%-0.65%-22.84%+0.33% 12.12B
+0.28%+1.87%-50.57%-69.19% 4.22B
-0.42%+2.19%-16.73%+56.93% 2.72B
-1.70%-0.78% - - 2.04B
+1.02%-1.48%-32.82%-71.90% 1.78B
-0.45%-2.20%-17.93%-15.88% 1.62B
-5.12%-5.72%-37.38%-40.79% 1.52B
Average -0.64%-0.28%-13.39%+2.67% 18.16B
Weighted average by Cap. +1.86%+0.12%-10.44%+22.03%

Financials

2026 *2027 *
Net sales 691M 595M 558M 510M 960M 66.03B 963M 6.62B 2.58B 33.33B 2.59B 2.54B 111B 845M 728M 682M 623M 1.17B 80.72B 1.18B 8.1B 3.16B 40.75B 3.17B 3.1B 135B
Net income -51.88M -44.71M -41.92M -38.26M -72.08M -4.96B -72.31M -497M -194M -2.5B -195M -191M -8.3B 18.93M 16.31M 15.29M 13.96M 26.3M 1.81B 26.38M 181M 70.78M 913M 71.06M 69.51M 3.03B
Net Debt -175M -151M -141M -129M -243M -16.71B -244M -1.68B -654M -8.44B -657M -642M -27.98B -273M -235M -220M -201M -379M -26.08B -380M -2.62B -1.02B -13.16B -1.02B -1B -43.65B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
28/08/26 US$179.87 -1.12% 553,529
27/08/26 US$181.91 +0.74% 442,313
26/08/26 US$180.57 -0.45% 506,040
25/08/26 US$181.39 -2.29% 639,693
24/08/26 US$185.65 +0.41% 622,292
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
179.87USD
Average target price
197.15USD
Spread / Average Target
+9.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock